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Aims To assess differences in diuretic dose requirements in patients treated with sacubitril/valsartan compared with
enalapril in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity
in Heart Failure (PARADIGM-HF) trial.
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Methods
and results
Overall, 8399 patients with New York Heart Association class II–IV heart failure and reduced LVEF were randomized
to sacubitril/valsartan 200mg bid or enalapril 10mg twice daily. Loop diuretic doses were assessed at baseline, 6, 12,
and 24months, and furosemide dose equivalents were calculated via multiplication factors (2x for torsemide and 40x
for bumetanide). Percentages of participants with reductions or increases in loop diuretic dose were determined.
At baseline, 80.8% of participants were taking any diuretics (n= 6290 for loop diuretics, n= 496 for other diuretics);
of those, recorded dosage data for loop diuretics were available on 5487 participants. Mean baseline furosemide
equivalent doses were 48.2mg for sacubitril/valsartan and 49.6mg for enalapril (P= 0.25). Patients treated with
sacubitril/valsartan were more likely to reduce diuretic dose and less likely to increase diuretic dose relative to
those randomized to enalapril at 6, 12, 24months post-randomization, with an overall decreased diuretic use of
2.0% (P= 0.02), 4.1% (P< 0.001), and 6.1% (P< 0.001) at 6, 12, and 24months, respectively, with similar findings in
an on-treatment analysis.
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Conclusion Treatment with sacubitril/valsartan was associated with more loop diuretic dose reductions and fewer dose increases
compared with enalapril, suggesting that treatment with sacubitril/valsartan may reduce the requirement for loop
diuretics relative to enalapril in patients with heart failure with reduced ejection fraction.
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Background
In the Prospective comparison of ARNI with ACEI to Deter-
mine Impact on Global Mortality and morbidity in Heart Failure
(PARADIGM-HF) trial, sacubitril/valsartan (formerly LCZ696)
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. reduced the primary composite outcome of cardiovascular death
or heart failure hospitalization compared to enalapril in patients
with symptomatic heart failure.1 Sacubitril inhibits the enzyme
neprilysin, which plays a role in the breakdown of natriuretic
peptides, increases natriuretic peptide levels, which may result in a
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natriuretic effect.2 Loop diuretics, frequently used in patients with
heart failure, can lead to neurohormonal activation,3,4 electrolyte
abnormalities, and worsening renal function,5 and higher doses of
diuretics have been associated with worse outcomes.6–8
The goal of this analysis was to investigate post-randomization
differences in diuretic use among participants randomized to sacu-
bitril/valsartan compared with enalapril in the PARADIGM-HF trial.
We hypothesized that sacubitril/valsartan would be associated with
reduced diuretic dose requirements compared with enalapril.
Methods
Patients
The study design of PARADIGM-HF has been previously reported.
Briefly, patients with New York Heart Association (NYHA) class II–IV
heart failure with reduced ejection fraction (≤ 40%) and mild eleva-
tion in natriuretic peptides entered sequential active run-in phases
in which they were up-titrated to enalapril 10mg bid followed by sacu-
bitril/valsartan 200mg bid. After run-in, they were randomized to sacu-
bitril/valsartan 200mg bid, or enalapril 10mg bid. Patients were fol-
lowed for a median of 27months. The trial complies with the Dec-
laration of Helsinki; locally appointed ethics committees approved
the research protocol and informed consent was obtained from all
subjects.
Assessment of diuretic use
Use of diuretics (non-loop and loop type) including name of drug
and dose were collected at baseline, 6, 12, and 24 months
post-randomization on case report forms. For loop diuretics,
furosemide dose equivalents were calculated, with bumetanide 1mg
or torsemide 20mg considered equivalent to 40mg of furosemide.9
Statistical analysis
Baseline characteristics were summarized by diuretic use (no diuretic,
non-loop diuretic, loop diuretic). For loop diuretic, categories were
created based on dose: < 20mg daily, 20–40mg daily, > 40mg daily).
Data from participants with missing dose information for loop diuretics
(n= 803) were excluded. Baseline characteristics between diuretic use
groups were compared with chi-square test for categorical variables
and ANOVA for continuous variables. The percentage of patients with
reductions or increases in loop diuretic dose was calculated at 6, 12,
and 24months post-randomization and compared between enalapril
and sacubitril/valsartan treatment arms via regression.
Results
Out of 8399 validly randomized patients in PARADIGM-HF, 80.8%
of participants were taking any diuretics [n= 6290 for loop diuret-
ics, n= 496 for other diuretics (e.g. thiazide)] at baseline. Of
those, recorded, dosage data for loop diuretics were available on
5487 participants out of 6290 (furosemide equivalent < 20mg,
n= 438, 7.3%; furosemide equivalent 20–40mg, n= 3625, 60.6%;
furosemide > 40mg, n= 1424, 23.8%). A total of 7259 participants
had diuretic doses available at baseline and at least at one additional
time point. Use of any diuretics was associated with higher NYHA ..
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.. class, lower ejection fraction, higher body mass index, greater like-
lihood of prior heart failure hospitalization, hypertension, diabetes,
atrial fibrillation, digoxin use, mineralocorticoid receptor antag-
onist (MRA) use, higher creatinine, higher N-terminal pro brain
natriuretic peptide (NT-proBNP), and lower incidence of ischaemic
aetiology (Table 1). Higher diuretic dose was associated with worse
NYHA class, higher likelihood of prior heart failure hospitalization,
hypertension, diabetes, atrial fibrillation, use of digoxin, higher cre-
atinine, and higher NT-proBNP. In a multivariable model, changes in
diuretic dose from baseline to 6months were positively associated
with baseline body mass index and NT-proBNP, and inversely asso-
ciated with baseline use and dose of MRA, digoxin, baseline weight,
and randomization to sacubitril/valsartan (all P< 0.01). Doses of
spironolactone and eplerenone at 6 and 12months were also asso-
ciated with 6 and 12-month diuretic changes, but the effect of
sacubitril/valsartan on diuretic dose reductions remained signifi-
cant after adjustment for MRA dose changes and post-baseline
changes in systolic blood pressure and weight. Systolic blood pres-
sure, weight, and MRA use and dose did not modify the effect of
sacubitril/valsartan on diuretic dose changes at 6 and 12months
(all P> 0.1).
Mean baseline furosemide equivalent doses were 48.2mg for
sacubitril/valsartan and 49.6mg for enalapril (P= 0.25). Participants
assigned to sacubitril/valsartan had more frequent diuretic dose
reductions and less frequent dose increases compared to those tak-
ing enalapril at 6, 12, and 24months (Figure 1). As a result, patients
randomized to sacubitril/valsartan had lower use of diuretics at
6months (net reduction 2.0%, P= 0.02), 12months (net reduction
4.1%, P< 0.001) and 24months (net reduction 6.1%, P< 0.001) rel-
ative to enalapril with similar differences seen in an on-treatment
analysis.
Discussion
We found that in PARADIGM-HF diuretic use at baseline was
associated with a more severe burden of illness. Patients random-
ized to sacubitril/valsartan had lower subsequent use of diuretics,
with fewer loop diuretic dose increases and more frequent dose
reductions compared with those taking enalapril.
Loop diuretic use has been associated in prior studies with
worse outcomes in heart failure, although the extent to which
diuretic use represents a marker for sicker patients and thus
increased risk, or plays a causal role remains unclear. Several
studies, including those with adjustment for the propensity to
be treated with loop diuretics, have documented an association
between loop diuretics and a greater risk for hospitalization or
death due to worsening heart failure, all-cause mortality, cardiovas-
cular death, and sudden cardiac death compared to non-use.5–8,10
There appears to be a dose-related association, such that higher
doses of diuretics are associated with greater risk compared with
lower doses.5
Several mechanisms have been proposed by which loop
diuretics may increase risk in heart failure. Loop diuretics,
through their actions on the sodium/potassium/2–chloride
co-transporter, lead to secretion of renin, with resulting neu-
rohormonal activation.3,11,12 Increased levels of plasma renin
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Table 1 Baseline characteristics by diuretic use groups
Characteristic No diuretics
(n= 1620)
Non-loop
diuretics
(n= 496)
Furosemide equivalent dose P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
< 20mg
(n= 438)
20–40mg
(n= 3625)
> 40mg
(n= 1424)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Randomized to sacubitril/valsartan, n (%) 811 (50.1) 223 (45.0) 206 (47.0) 1847 (51.0) 688 (48.3) 0.06
Age, years, mean (SD) 64 (11) 65 (11) 64 (11) 64 (11) 63 (12) 0.03
Female sex, n (%) 346 (21.4) 131 (26.4) 101 (23.1) 788 (21.7) 277 (19.5) 0.02
Caucasian, n (%) 985 (60.8) 311 (62.7) 326 (74.4) 2340 (64.6) 974 (68.4) <0.001
NYHA class III/IV, n (%) 266 (16.5) 163 (32.9) 147 (33.6) 796 (22.0) 435 (30.6) <0.001
Ejection fraction, mean (SD) 30.3 (5.9) 31.2 (5.7) 30.3 (5.9) 29.3 (6.2) 28.0 (6.7) <0.001
Body mass index, kg/m2, mean (SD) 27.0 (4.8) 27.9 (5.6) 27.6 (5.2) 28.1 (5.4) 29.9 (6.3) <0.001
Prior HF hospitalization, n (%) 869 (53.6) 235 (47.4) 278 (63.5) 2337 (64.5) 1019 (71.6) <0.001
Hypertension, n (%) 1091 (67.3) 367 (74.0) 320 (73.1) 2571 (70.9) 988 (69.4) 0.01
Diabetes mellitus, n (%) 453 (28.0) 150 (30.2) 116 (26.5) 1268 (35.0) 638 (44.8) <0.001
Atrial fibrillation, n (%) 472 (29.1) 181 (36.5) 177 (40.4) 1305 (36.0) 617 (43.3) <0.001
Systolic BP, mmHg, mean (SD) 122 (15) 124 (15) 123 (14) 121 (15) 120 (16) <0.001
ICD, n (%) 207 (12.8) 36 (7.3) 44 (10.0) 527 (14.5) 332 (23.3) <0.001
CRT, n (%) 84 (5.2) 16 (3.2) 17 (3.9) 221 (6.1) 179 (12.6) <0.001
ACEi use, n (%) 1213 (74.9) 364 (73.4) 354 (80.8) 2817 (77.7) 1135 (79.7) 0.001
ARB use, n (%) 409 (25.2) 133 (26.8) 83 (18.9) 818 (22.6) 298 (20.9) 0.002
Beta-blocker use, n (%) 1496 (92.3) 463 (93.3) 405 (92.5) 3357 (92.6) 1336 (93.8) 0.52
Digoxin use, n (%) 318 (19.6) 171 (34.5) 133 (30.4) 1109 (30.6) 536 (37.6) <0.001
MRA use, n (%) 772 (47.7) 227 (45.8) 293 (66.9) 2091 (57.7) 856 (60.1) <0.001
Serum creatinine, mg/dL, mean (SD) 1.07 (0.25) 1.07 (0.26) 1.11 (0.30) 1.12 (0.30) 1.21 (0.33) <0.001
NT-proBNP, pg/mL, median (IQR) 1304 (768–2566) 1392 (806–2501) 1599 (905–3134) 1684 (921–3396) 2026 (1067–4207) <0.001
Ischaemic aetiology, n (%) 1082 (66.8) 324 (65.3) 282 (64.4) 2062 (56.9) 783 (55.0) <0.001
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CRT, cardiac resynchronization therapy; HF, heart failure; ICD,
implantable cardioverter defibrillator; IQR, interquartile range; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA,
New York Heart Association; SD, standard deviation.
activity, suggestive of neurohormonal activation, have been
independently associated with increased risk of mortality in
patients with heart failure.13 Diuretic use in the presence of
neurohormonal activation has also been shown to portend worse
outcomes.14
The reduced relative need for diuretics in patients random-
ized to sacubitril/valsartan may potentially be secondary to the
natriuretic effects of sacubitril or the presumed improvement in
haemodynamics that may occur with sacubitril/valsartan. Sacubi-
tril/valsartan is not associated with weight loss, however, sug-
gesting that any diuretic effect is weak. While there are not
any demonstrated haemodynamic data in heart failure patients
treated with sacubitril/valsartan, sacubitril/valsartan is known to
decrease NT-proBNP substantially within 4weeks of therapy,
consistent with a relatively rapid improvement in haemodynam-
ics with administration.15 Since investigators were blinded to
therapy, diuretic dose reductions were prompted by changes in
patient symptoms, which improved in patients randomized to
sacubitril/valsartan.16 Conversely, it is also possible that sacubi-
tril/valsartan lowered blood pressure more than enalapril, necessi-
tating reduction of diuretic doses.
Diuretic use has been implicated in greater risk for hypotension
in patients receiving renin–angiotensin system inhibitors; if diuretic ..
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. doses were not down-titrated in patients taking sacubitril/valsartan
in response to reduced clinical need, this may have resulted in
over-diuresis that could contribute to hypotension. This possi-
bility underscores the importance of assessment and potential
adjustment of diuretic doses prior to and following initiation of
an angiotensin receptor neprilysin inhibitor.
Several limitations of this analysis should be noted. The differ-
ential use of diuretics among participants randomized to sacubi-
tril/valsartan compared to enalapril was not a pre-specified analysis.
Doses of diuretics were not available for all participants, which
could lower the precision of dose change comparisons between
groups. We compared diuretic use at discrete time points and may
have missed interim changes in diuretic use that may not have
been captured at study visits. Diuretic dose changes were not
available at earlier time points after randomization, which could
have been of interest given the quick onset of NT-proBNP reduc-
tion by sacubitril/valsartan. Additionally, there was limited infor-
mation on medication dose changes during the run-in period of
the PARADIGM-HF trial; these data could have further informed
trends on diuretic dose adjustments after initiation of sacubi-
tril/valsartan. Reasons for diuretic dose changes were not captured
in the study. Lastly, there could be incomplete capture of non-loop
diuretic changes or addition of MRAs.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Changes in diuretic use during PARADIGM-HF at 6months, 1 year, and 2 years by treatment arm based on (A) intention-to-treat
(ITT) and (B) per protocol treatment.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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In summary, treatment with sacubitril/valsartan was associated
with more loop diuretic dose reductions and fewer dose increases
compared with enalapril in the PARADIGM-HF study, suggesting
that treatment with sacubitril/valsartan may reduce the relative
requirement for loop diuretics in patients with heart failure with
reduced ejection fraction. These findings may be relevant to clin-
icians treating patients concomitantly with sacubitril/valsartan and
diuretics.
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